top of page

IO Biotech CEO Mai-Britt Zocca discusses the phase 3 pivotal trial result of the cancer vaccine Cylembio in first line advanced melanoma - and the company's strategy ahead

  • blonca9
  • Aug 15, 2025
  • 1 min read

Dr. Zocca describes the results of the trial, which showed a 19.4 months vs. 11.0 months mPFS benefit versus pembro alone, but narrowly missed statistical significance. She shares her take on the totality of the data and discusses the road ahead, including a Q3 meeting the company will have with FDA.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTV

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC_IB_Stacked_logo.png

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

​

​Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

Learn more

bottom of page